Cleared Traditional

HAEMOGLOBIN REAGENT - CYANMETHAEMOGLOBIN METHOD (K870363) - FDA 510(k) Clearance

Class II Hematology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K870363 · Trace Scientific , Ltd. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1987
Decision
47d
Days
Class 2
Risk

K870363 is an FDA 510(k) clearance for the HAEMOGLOBIN REAGENT - CYANMETHAEMOGLOBIN METHOD. Classified as Whole Blood Hemoglobin Determination (product code KHG), Class II - Special Controls.

Submitted by Trace Scientific , Ltd. (Clayton, Vic 3168, AU). The FDA issued a Cleared decision on March 16, 1987 after a review of 47 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7500 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Trace Scientific , Ltd. devices

Submission Details

510(k) Number K870363 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 28, 1987
Decision Date March 16, 1987
Days to Decision 47 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
66d faster than avg
Panel avg: 113d · This submission: 47d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KHG Whole Blood Hemoglobin Determination
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7500
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - KHG Whole Blood Hemoglobin Determination

All 38
Devices cleared under the same product code (KHG) and FDA review panel - the closest regulatory comparables to K870363.
AnemoCheck Home
K221508 · Sanguina, Inc. · Sep 2023
ABBOTT VISION HEMOGLOBIN (MODIFICATION)
K953221 · Abbott Laboratories · Sep 1995
REFLOTRON HEMOGLOBIN TEST TABS
K934064 · Boehringer Mannheim Corp. · Dec 1993
EASY-TEST HEMOGLOBIN (HGB) ITEM #16685
K872653 · Em Diagnostic Systems, Inc. · Jul 1987
VISION(TM) HEMOGLOBIN
K862202 · Abbott Laboratories · Aug 1986
KODAK EKTACHEM CLINICAL CHEMISTRY SLIDE HB
K854139 · Eastman Kodak Company · Nov 1985